Compare Rockwell Automation (ROK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rockwell Automation vs State Street SPDR S&P Biotech ETF — how do they compare? Rockwell Automation trades at $432.59 (market cap $48.21B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Rockwell Automation is far larger — about 4.8× State Street SPDR S&P Biotech ETF's market cap, and Rockwell Automation pays a 1.27% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rockwell Automation for 74 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| ROK | XBI | |
|---|---|---|
Market Cap | $48.21B | $10.11B |
Volume | 953,342 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $495.08 | $169.55 |
52-Week Low | $333.75 | $104.99 |
Typical Hold Time | 74 Days | 38 Days |
Enterprise Value | $51.34B | — |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rockwell Automation (ROK) trades at $434.14, down 1.76% on the day, with a bearish technical signal. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Key financials show strong profitability with a 49.09% gross margin and 34.47% ROE, though the P/E ratio of 40.65 suggests a premium valuation. Recent news highlights the company's focus on industrial automation growth, cybersecurity, and AI integration.
The outlook is mixed: analyst consensus is a Buy with a $489.89 price target, but technicals indicate near-term pressure. Investment opportunities lie in continued earnings beats and automation demand, while risks include high valuation sensitivity and macroeconomic headwinds affecting industrial spending.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
